Yellow fever

Monath, 2012, Yellow fever vaccine, 870

Vasconcelos, 2010, Yellow fever in Brazil: thoughts and hypotheses on the emergence in previously free areas, Rev Saude Pública, 44, 1144, 10.1590/S0034-89102010005000046

Barrett, 2007, Yellow fever: a disease that has yet to be conquered, Annu Rev Entomol, 52, 209, 10.1146/annurev.ento.52.110405.091454

Jentes, 2011, The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever, Lancet Infect Dis, 11, 622, 10.1016/S1473-3099(11)70147-5

World Health Organization, 2010, Yellow fever surveillance and outbreak response: revision of case definitions, October 2010, Wkly Epidemiol Rec, 85, 465

Souza, 2010, Detection of a new yellow fever virus lineage within the South American genotype I in Brazil, J Med Virol, 82, 175, 10.1002/jmv.21606

Tuboi, 2007, Clinical and epidemiologic characteristics of yellow fever in Brazil: analysis of reported cases, 1998–2002, Trans R Soc Trop Med Hyg, 101, 169, 10.1016/j.trstmh.2006.04.001

Monath, 2002, Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial, Am J Trop Med Hyg, 66, 533, 10.4269/ajtmh.2002.66.533

Moreno, 2013, Yellow fever epizootics in non-human primates, São Paulo state, Brazil, 2008–2009, Rev Inst Med Trop Sao Paulo, 55, 45, 10.1590/S0036-46652013000100008

Bryant, 2007, Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas, PLoS Pathog, 3, e75, 10.1371/journal.ppat.0030075

Nájera, 2013

Goenaga, 2012, Isolation of yellow fever virus from mosquitoes in Misiones province, Argentina, Vector Borne Zoonotic Dis, 12, 986, 10.1089/vbz.2011.0730

Vasconcelos, 2004, Genetic divergence and dispersal of yellow fever virus, Brazil, Emerg Infect Dis, 10, 1578, 10.3201/eid1009.040197

Vasconcelos, 2003, Isolations of yellow fever virus from Haemagogus leucocelaenus in Rio Grande do Sul State, Brazil, in the Southern Cone, Trans R Soc Trop Med Hyg, 97, 60, 10.1016/S0035-9203(03)90023-X

Almeida, 2014, Surveillance for yellow fever virus in non-human primates in Southern Brazil, 2001–2011: a tool for prioritizing human populations for vaccination, PLoS Negl Trop Dis, 8, e2741, 10.1371/journal.pntd.0002741

Cardoso, 2010, Yellow fever virus isolation from Haemagogus leucocelaenus and Aedes serratus mosquitoes: southern Brazil, 2008, Emerg Infect Dis, 16, 1918, 10.3201/eid1612.100608

Romano, 2014, Yellow fever outbreaks in unvaccinated populations, Brazil, 2008–2009, PLoS Negl Trop Dis, 8, e2740, 10.1371/journal.pntd.0002740

Markoff, 2013, Yellow fever outbreak in Sudan, N Engl J Med, 368, 689, 10.1056/NEJMp1300772

Garske, 2014, Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data, PLoS Med, 10.1371/journal.pmed.1001638

Robertson, 1996, Yellow fever: a decade of reemergence, JAMA, 276, 1157, 10.1001/jama.1996.03540140045025

World Health Organization. Epidemiology of yellow fever in the African region. WHO/OR-02 March 2012.

Monath, 1972, Surveillance of yellow fever in Nigeria, 1970–1971, Nigerian Med J, 21, 178

Bonney, 2013, Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana, PLoS Negl Dis, 7, e2435, 10.1371/journal.pntd.0002435

Beck, 2013, Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into East and West Africa, PLoS Negl Trop Dis, 7, e1910, 10.1371/journal.pntd.0001910

Germain, 1980, Yellow fever in the Gambia, 1978–1979: entomological aspects and epidemiological correlations, Am J Trop Med Hyg, 29, 929, 10.4269/ajtmh.1980.29.929

Sall, 2010, Yellow fever exhibits slower evolutionary dynamics than dengue virus, J Virol, 84, 765, 10.1128/JVI.01738-09

Mutebi, 2001, Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa, J Virol, 75, 6999, 10.1128/JVI.75.15.6999-7008.2001

Stock, 2013, Biological and phylogenetic characteristics of yellow fever virus. Lineages from West Africa, J Virol, 87, 2895, 10.1128/JVI.01116-12

Vasconcelos, 2001, An epidemic of jungle yellow fever in Brazil, 2000. Implications of climatic alterations in disease spread, J Med Virol, 65, 598, 10.1002/jmv.2078

Mondet, 1996, Les Risques D’Épidémisation Urbaine de la Fièvre Jaune au Brésil par les Vecteurs de la Dengue, Bull Soc Pathol Exot, 89, 107

Kaufmann, 2011, Molecular mechanisms involved in the early steps of Flavivirus cell entry, Microbes Infect, 13, 1, 10.1016/j.micinf.2010.09.005

Perera, 2010, Structural proteomics of dengue virus, Curr Opin Microbiol, 11, 369, 10.1016/j.mib.2008.06.004

Monath, 2003, Pathogenesis and pathophysiology of yellow fever, Adv Virus Dis, 60, 343, 10.1016/S0065-3527(03)60009-6

Quaresma, 2013, Immunity and immune response, pathology and pathologic changes. Progresses and challenges in the immunopathology of yellow fever, Rev Med Virol, 23, 305, 10.1002/rmv.1752

Theiler, 1951, The virus, 46

Tesh, 2001, Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). 1. Virologic, biochemical and immunologic studies, J Infect Dis, 183, 1431, 10.1086/320199

Quaresma, 2005, Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever, Acta Trop, 94, 116, 10.1016/j.actatropica.2005.03.003

Quaresma, 2006, Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGFβ, TNFα and NK cells activity, Virology, 345, 22, 10.1016/j.virol.2005.09.058

Quaresma, 2006, Immunohistochemical examination of the role of FAS ligand and lymphocytes in the pathogenesis of human liver yellow fever, Virus Res, 116, 91, 10.1016/j.virusres.2005.08.019

Quaresma, 2006, Midzonal lesion in the yellow fever: a specific pattern of liver injury caused by direct virus action and by immune anti-inflammatory response, Med Hypotheses, 47, 618, 10.1016/j.mehy.2006.01.060

Quaresma, 2007, Hepatocyte lesions and cellular immune response in yellow fever infection, Trans R Soc Trop Med Hyg, 101, 161, 10.1016/j.trstmh.2006.02.019

Theiler, 1975, The relative resistance of dengue immune monkeys to yellow fever virus, Am J Trop Med Hyg, 24, 115, 10.4269/ajtmh.1975.24.115

Xiao, 2003, Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses, Am J Trop Med Hyg, 68, 695, 10.4269/ajtmh.2003.68.695

Monath, 1981, Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations in the acute necrosis of B cell areas of lymphoid tissues, Am J Trop Med Hyg, 30, 431, 10.4269/ajtmh.1981.30.431

ter Meulen, 2004, Activation of the cytokine network and unfavorable outcome in patients with yellow fever, J Infect Dis, 190, 1821, 10.1086/425016

Li, 2008, Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes, Int J Clin Exp Pathol, 1, 169

Triviño, 2008, Dengue-yellow fever sera cross-reactivity. Challenges for diagnosis, Rev Saude Pública, 10, 299, 10.1590/S0124-00642008000200010

Weidmann, 2010, Improved DNA probe based assay for the detection of African and South-American yellow fever virus strains, J Clin Virol, 48, 187, 10.1016/j.jcv.2010.04.013

Domingo, 2012, Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories, J Clin Microbiol, 50, 4054, 10.1128/JCM.01799-12

Nunes, 2011, Evaluation of two molecular methods for the detection of yellow fever virus genome, J Virol Methods, 174, 29, 10.1016/j.jviromet.2011.02.025

Kwallah, 2013, A real-time reverse transcription loop-mediated isothermal amplification assay for the rapid detection of yellow fever virus, J Virol Methods, 10.1016/j.jviromet.2013.05.004

Escadafal, 2014, Rapid molecular assays for the detection of yellow fever virus in low-resource settings, PLoS Negl Trop Dis, 8, e2730, 10.1371/journal.pntd.0002730

World Health Organization, 2010, WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13–14 May 2009, Vaccine, 28, 8236, 10.1016/j.vaccine.2010.10.070

Lindsey, 2008, Adverse event reports following yellow fever vaccination, Vaccine, 26, 6077, 10.1016/j.vaccine.2008.09.009

Khromava, 2005, Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events, Vaccine, 23, 3256, 10.1016/j.vaccine.2005.01.089

Monath, 2006, A live, attenuated recombinant vaccine against West Nile virus, Proc Natl Acad Sci USA, 103, 6694, 10.1073/pnas.0601932103

Domingo, 2011, Detection of yellow fever 17D genome in urine, J Clin Microbiol, 49, 760, 10.1128/JCM.01775-10

Lamson, 2014, An unusual case of influenza-like illness after yellow fever vaccination, J Clin Virol, 60, 67, 10.1016/j.jcv.2014.01.020

Roukens, 2008, Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial, PLoS ONE, 3, e1993, 10.1371/journal.pone.0001993

Vratskikh, 2013, Dissection of antibody specificities induced by yellow fever vaccination, PLoS Pathog, 9, e1003458, 10.1371/journal.ppat.1003458

Mason, 1973, Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine, Appl Microbiol, 25, 539, 10.1128/AEM.25.4.539-544.1973

Julander, 2011, Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model, Vaccine, 29, 6008, 10.1016/j.vaccine.2011.06.034

Hepburn, 2006, Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine, Vaccine, 24, 2843, 10.1016/j.vaccine.2005.12.055

Neves, 2009, TLR expression and NK cell activation after human yellow fever vaccination, Vaccine, 27, 5543, 10.1016/j.vaccine.2009.07.028

Kohler, 2012, The early cellular signatures of protective immunity induced by live viral vaccination, Eur J Immunol, 42, 2363, 10.1002/eji.201142306

Querec, 2009, Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans, Nat Rev Immunol, 10, 116, 10.1038/ni.1688

Gaucher, 2009, Yellow fever induces integrated multilineage and polyfunctional immune responses, J Exp Med, 205, 3119, 10.1084/jem.20082292

Pulendran, 2009, Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology, Nat Rev Immunol, 9, 741, 10.1038/nri2629

Silva, 2011, Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults, Vaccine, 29, 583, 10.1016/j.vaccine.2010.08.046

Gotuzzo, 2013, Review article efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years, Am J Trop Med Hyg, 89, 434, 10.4269/ajtmh.13-0264

Belmusto-Worn, 2005, Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YELLOW FEVER-VAX) in healthy infants and children in Peru, Am J Trop Med Hyg, 72, 189, 10.4269/ajtmh.2005.72.189

Miller, 2008, Human effector and memory CD8+ responses to smallpox and yellow fever vaccines, Immunity, 28, 710, 10.1016/j.immuni.2008.02.020

Akondy, 2009, The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response, J Immunol, 183, 7919, 10.4049/jimmunol.0803903

Vasconcelos, 2001, Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases, Lancet, 358, 91, 10.1016/S0140-6736(01)05326-0

Martin, 2001, Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases, Lancet, 358, 98, 10.1016/S0140-6736(01)05327-2

Chan, 2001, Hepatitis and death following vaccination with 17D-204 yellow fever vaccine, Lancet, 358, 121, 10.1016/S0140-6736(01)05341-7

Monath, 2010, Short report: suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States, Am J Trop Med Hyg, 82, 919, 10.4269/ajtmh.2010.10-0001

Gershman, 2012, Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data, Vaccine, 30, 5038, 10.1016/j.vaccine.2012.04.067

Monath, 2012, Review of the risks and benefits of yellow fever vaccination including some new analyses, Expert Rev Vaccines, 11, 427, 10.1586/erv.12.6

Seligman, 2011, Yellow fever virus vaccine—associated deaths in young women, Emerg Infect Dis, 17, 1891, 10.3201/eid1710.101789

Roukens, 2011, Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study, PLoS ONE, 6, e27753, 10.1371/journal.pone.0027753

Belsher, 2007, Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease, Vaccine, 25, 8480, 10.1016/j.vaccine.2007.08.061

Bigham, 2011, Host genetic risk factors for West Nile virus infection and disease progression, PLoS ONE, 6, e24745, 10.1371/journal.pone.0024745

Pulendran, 2008, Case of yellow-fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes, J Infect Dis, 198, 500, 10.1086/590187

McMahon, 2007, Neurologic disease associated with 17D-204 fever vaccination: a report of 15 cases, Vaccine, 25, 1727, 10.1016/j.vaccine.2006.11.027

Glass, 2006, CCR5 deficiency increases risk of symptomatic West Nile virus infection, J Exp Med, 203, 35, 10.1084/jem.20051970

World Health Organization. Detection and investigation of serious adverse events following yellow fever vaccination: guidance from an informal consultation of experts, 18–19 November.

http://www.france24.com/en/20130706-interview-malcolm-brabant-bbc-correspondent-yellow-fever-vaccination-psychotic-episodes.

Traiber, 2011, Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk, J Pediatr (Rio J), 87, 269

Kuhn, 2011, Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk, Can Med Assoc J, 183, E243, 10.1503/cmaj.100619

Monath, 2008, Treatment of yellow fever, Antiviral Res, 78, 116, 10.1016/j.antiviral.2007.10.009

Julander, 2011, Treatment of yellow fever virus with an adenovirus-vectored interferon DEF201, in a hamster model, Antimicrob Agents Chemother, 55, 2067, 10.1128/AAC.01635-10

Sbrana, 2004, Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease, Am J Trop Med Hyg, 71, 306, 10.4269/ajtmh.2004.71.306

Vellozzi, 2006, Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996–2004, Am J Trop Med Hyg, 75, 333, 10.4269/ajtmh.2006.75.333

ter Meulen, 2004, Activation of the cytokine network and unfavourable outcome in patients with yellow fever, J Infect Dis, 190, 1821, 10.1086/425016

Monath, 2011, A clinical trial of an inactivated, cell culture vaccine against yellow fever, N Engl J Med, 364, 1326, 10.1056/NEJMoa1009303

Wiysonge, 2008, Yellow fever control in Cameroon: where are we now and where are we going?, BMC Med, 6, 3, 10.1186/1741-7015-6-3

Briand, 2009, Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach, PLoS Negl Trop Dis, 3, e483, 10.1371/journal.pntd.0000483

Breugelmans, 2013, Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010, Vaccine, 31, 1819, 10.1016/j.vaccine.2013.01.054